4/A: Inhibikase Therapeutics Director Amends Stock Option Exercise Price

Inhibikase Therapeutics, Inc. Director Vincent Aurentz filed an amended Form 4 to correct the exercise price of a previously reported stock option award.

Summary

• An amendment to a Form 4 was filed on July 2, 2025, by Vincent Aurentz, a Director of Inhibikase Therapeutics, Inc. (IKT).
• The purpose of this amendment is solely to correct an inadvertently reported incorrect exercise price for a stock option award originally granted on February 21, 2025.
• The corrected exercise price for the 134,427 stock options is $2.97.
• The options will vest and become exercisable in two substantially equal installments on the first and second anniversaries of February 21, 2025, subject to Vincent Aurentz's continued services.
• The stock options have an expiration date of February 21, 2035.

Sentiment

Score: 5

Explanation: The filing is a routine amendment to correct a clerical error in a previous filing, indicating no material positive or negative operational or financial news for the company.

Positives

• The filing clarifies the precise terms of a compensation award for a director, ensuring accuracy in public disclosures.

Negatives

• The initial error in reporting the exercise price indicates a minor administrative oversight, though it has been corrected.

Risks

• No new risks are introduced by this amendment; it addresses and corrects a previous reporting inaccuracy.

Future Outlook

The stock options granted to Director Vincent Aurentz are scheduled to vest in two substantially equal installments on the first and second anniversaries of February 21, 2025, contingent on his continued service.

Management Comments

• The Reporting Person's Form 4 filed with the SEC on February 25, 2025 inadvertently reported an incorrect exercise price with respect to the stock option award originally granted on February 21, 2025. This amendment is being filed solely to correct the exercise price.

Industry Context

This filing is a routine compliance amendment related to insider compensation, which is common across all publicly traded companies. It does not provide insights into broader industry trends or competitive dynamics.

Comparison to Industry Standards

• This filing is a standard regulatory amendment (Form 4/A) to correct a clerical error in an insider transaction report. Such amendments are a common part of SEC compliance across all industries and do not lend themselves to direct comparison with specific company projects or financial results.

Related Party Transactions

• This amendment corrects the terms of a stock option award granted to Vincent Aurentz, a Director, which is a form of related party compensation.

Stakeholder Impact

• Shareholders: Provides clarity and accuracy regarding the terms of a director's stock option compensation.
• Employees: No direct impact on general employees.
• Management: Ensures accurate reporting of compensation for a director.

Next Steps

• The stock options will vest in two substantially equal installments on the first and second anniversaries of February 21, 2025, subject to the Reporting Person's continued services.

Key Dates

Keywords

Inhibikase Therapeutics, IKT, SEC Form 4/A, Stock Option, Director Compensation, Beneficial Ownership, Amendment, Exercise Price